New hope for pancreatic cancer: experimental combo enters human testing

NCT ID NCT04104672

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times

Summary

This early-stage study tests a new drug called AB680 combined with three other medications (zimberelimab, nab-paclitaxel, and gemcitabine) in people with advanced pancreatic cancer that has not been treated before. The main goals are to check safety and find the right dose. About 196 participants will take part. This is not a cure but aims to control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Los Angeles, California, 90025, United States

  • Research Site

    Santa Monica, California, 90404, United States

  • Research Site

    St Louis, Missouri, 63110, United States

  • Research Site

    New York, New York, 10016, United States

  • Research Site

    New York, New York, 10032, United States

  • Research Site

    New York, New York, 10065, United States

  • Research Site

    Oklahoma City, Oklahoma, 73104, United States

  • Research Site

    Philadelphia, Pennsylvania, 19104, United States

  • Research Site

    Pittsburgh, Pennsylvania, 15232, United States

  • Research Site

    Nashville, Tennessee, 37203, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    San Antonio, Texas, 78229, United States

  • Research Site

    Madison, Wisconsin, 53792, United States

Conditions

Explore the condition pages connected to this study.